Sigvotatug vedotin clinical trials
How each study uses sigvotatug vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sigvotatug vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Seagen, a wholly owned subsidiary of Pfizer (3) · Pfizer (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test sigvotatug vedotin.
- Jun 2027A Study of Sigvotatug Vedotin in Advanced Solid TumorsPhase 1 · Seagen, a wholly owned subsidiary of Pfizer
Studies
Open first, then newest update. How each study uses sigvotatug vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.RecruitingPhase 3PfizerNCT06758401Written as Sigvotatug Vedotin
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingPhase 1Seagen, a wholly owned subsidiary of PfizerNCT04389632Written as sigvotatug vedotin
- A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT06012435Written as sigvotatug vedotin
- A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedPhase 1Seagen, a wholly owned subsidiary of PfizerNCT06549816Written as sigvotatug vedotin
Given beside what is tested · 1 — sigvotatug vedotin is usual care or a partner of the new treatment
Codes
What other systems call sigvotatug vedotin · ClinicalTrials.gg INT017721
- UNII (FDA) QX0ONY0O9TSIGVOTATUG VEDOTINOne source FDA
- NCI Thesaurus C203047Sigvotatug VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QX0ONY0O9T | SIGVOTATUG VEDOTIN | One source FDA |
| NCI Thesaurus | C203047 | Sigvotatug Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.